INTRODUCTION AND OBJECTIVES: Big Data in healthcare amasses different types of information from multiple sources with the promise of improving healthcare delivery. However, the extent to which patient-generated data can improve upon administrative claims to predict outcomes remains unclear. In this context, we compared predictive models composed of claims-based and patient-reported health status measures in predicting life expectancy for men with prostate cancer.
METHODS: We identified men age>65 diagnosed with prostate cancer from 2004-2013 in the SEER-CAHPS database. SEER-CAHPS combines cancer registry data with Medicare claims and CAHPS surveys, which captures patient-reported health and care experience. For each patient, we measured baseline demographics, cancer characteristics, claims-based health status (eg, Charlson Comorbidity Index [CCI], Function-Related Indicators), and patientreported health status (eg, overall, mental, and functional health). We then constructed 5 models composed of different data types: 1) demographics; 2) demographics and cancer data; 3) demographics, cancer data, and claims-based health status; 4) demographics, cancer data, and patient-reported health status; and 5) all categories. For each model, we performed competing risk regression and evaluated the discriminatory ability of each model to predict other cause mortality by comparing the area under the receiver operator curve (AUC).
RESULTS: Among 3,444 men diagnosed with prostate cancer, 7.4% died of prostate cancer and 19.5% died of other causes. In model 5, men with CCI score>0 and overall health of Fair/Poor had increased likelihood of other cause mortality compared to men with CCI score of 0 or Excellent/Very Good health (p<0.001), respectively. As depicted in the Figure CONCLUSIONS: Models using patient-generated data performed similarly to claims-based models in predicting other cause mortality for men with prostate cancer. The development of life expectancy tools should focus on data availability and fidelity to optimize dissemination and implementation. . We sought to create a tool to predict personalized sexual, urinary, bowel, and hormonal function outcomes after RP, RT and AS.
METHODS: The CEASAR Study is a multicenter, prospective, observational study of men diagnosed with localized prostate cancer from 2011 to 2012. 2,138 men were followed from enrollment to 5 years with the Expanded Prostate Cancer Index short form (EPIC-26). Responses to the 26 questions are aggregated into 5 domain scores (sexual, urinary irritative, urinary incontinence, bowel, hormonal). Comprehensive models to predict domain scores were fit, including all available covariates (age, race, pre-treatment PSA, biopsy grade, BMI, EPIC-26 baseline function, treatment, and scores measuring comorbidity, general QOL and psychosocial health.) We fit parsimonious models for each domain with factors selected based on clinical considerations and statistical performance. The parsimonious and comprehensive models were compared using a 300-iteration bootstrap approach. Adjusted Rsquared values were compared and calibration plots developed to evaluate the performance of the parsimonious models versus the comprehensive models. A web-based tool was developed from the parsimonious models.
RESULTS: The prediction models achieved adjusted Rsquared values of 0.388, 0.245, 0.217, 0.234, and 0.348 for sexual function, urinary incontinence, urinary irritative, bowel, and hormonal domains, respectively. Differences in R-squared values between the comprehensive and parsimonious models were small in magnitude and not statistically significant. Calibration was excellent (Figure 1 ). The web-based tool may be found at https://statez.shinyapps.io/ PCDSPred/.
CONCLUSIONS: Functional outcomes after treatment for localized prostate cancer can be predicted at the time of diagnosis based on age, race, PSA, biopsy grade, baseline function, and a general question regarding overall health. Providers and patients can use this prediction tool to inform SDM.
